Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings

Journal of Gastrointestinal Cancer

Volumn 50, Issue 1, 2019, Pages 16-22

  Houts, Arthur C ^a   Ogale, Sarika ^b   Zafar, Yousuf ^c   Hubbard, Joleen M ^d   Satram Hoang, Sacha ^e   Sommer, Nicolas ^b   Walker, Mark S ^a  

^a Vector Oncology   (United States)

^b GENENTECH INC   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e QD Research Inc   (United States)

Author keywords

Overall survival; Real world outcomes; Standard chemotherapy backbones; Tumor location; VEGF inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL OUTCOME; COMMUNITY; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; HEALTH HAZARD; HEALTH STATUS; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MONOTHERAPY; OBSERVATIONAL STUDY; ONCOGENE K RAS; ONCOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION; COLORECTAL TUMOR; FEMALE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BEVACIZUMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGRESSION-FREE SURVIVAL; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85031928555     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-017-0017-8     Document Type: Article

References (21)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 10.3322/caac.21387
2. Hu CY, Bailey CE, You YN, Skibber JM, Rodriguez-Bigas MA, Feig BW, et al. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015;150(3):245–51. 10.1001/jamasurg.2014.2253
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47
4. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30. 10.1200/JCO.2004.09.046
5. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. 10.1200/JCO.2006.09.0928
6. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96(2):206–12
7. Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. The role of salvage treatment in advanced colorectal cancer. Crit Rev Oncol Hematol. 2009;71(1):53–61
8. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23(20):4553–60. 10.1200/JCO.2005.17.749
9. Tabernero J, van Cutsem E, Lakomy R, Prausova J, Ruff P, van Hazel G, et al. Results from VELOUR, a phase III study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer Abstract 6LBA. Paper presented at the ECCO-ESMO 2011, Stockholm Sweeden,
10. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. 10.1016/S0140-6736(12)61900-X
11. Zaniboni A. New active drugs for the treatment of advanced colorectal cancer. World J Gastrointest Surg. 2015;7(12):356–9. 10.4240/wjgs.v7.i12.356
12. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. 10.1016/S1470-2045(12)70477-1
13. Kubicka S, Greil R, Andre T, Bennouna J, Sastre J, Van Cutsem E, et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013;24(9):2342–9. 10.1093/annonc/mdt231
14. The National Comprehensive Cancer Network (NCCN) (2016) Clinical Practice Guidelines in Oncology: Colon Cancer, Version 2.2016. The National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 22 Feb 2016
15. Amgen (2015) Drug Label for Panitumumab. Amgen, Inc. http://pi.amgen.com/united_states/vectibix/vectibix_pi.pdf. Accessed 11 May 2015
16. Bristol-Myers Squibb and Lilly (2015) Cetuximab Drug Label. Bristol-Myers Squibb and Lilly. http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed 11 May 2015
17. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil BH, et al. (2016) Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). ASCO Meeting Abstracts 34 (15_suppl):3504
18. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74. 10.1016/S0140-6736(10)61381-5
19. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. 10.1200/JCO.2007.14.9930
20. Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, et al. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol. 2015;15:37. 10.1186/s12876-015-0266-6
21. von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140(9):1607–14. 10.1007/s00432-014-1678-3